DFCM
MLYS icon

Dark Forest Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Dark Forest Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-126,726
Closed -$1.71M – 1363
2025
Q2 		$1.71M Buy
126,726
+106,721
+533% +$1.55M 0.07% 516
2025
Q1 		$318K Buy
+20,005
New +$230K 0.01% 1050

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dark Forest Capital Management's MLYS Position: Q3 2025 in Review

Dark Forest Capital Management sold out of Mineralys Therapeutics (MLYS) in Q3 2025, closing a stake of 126,726 shares — an estimated $1.71M sold.

Dark Forest Capital Management first reported a position in MLYS in Q1 2025 and held it in 2 quarters. The position peaked at $1.71M in Q2 2025. 193 funds tracked by Wall St. Rank hold MLYS as of Q3 2025.

  • Dark Forest Capital Management reported no remaining Mineralys Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Dark Forest Capital Management sold 126,726 Mineralys Therapeutics shares in Q3 2025, an estimated $1.71M.
  • Dark Forest Capital Management first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 2 quarters.
  • Dark Forest Capital Management's Mineralys Therapeutics position peaked at $1.71M in Q2 2025.
  • 193 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2025.

Based on Dark Forest Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.